Profil de l'entreprise

Vous venez de lire:

Opdivo™ (nivolumab) demonstrates superior survival compared to standard of care (docetaxel) for previously-treated squamous non-small cell lung cancer in phase 3 trial

Nouvelles fournies par

Bristol-Myers Squibb Canada

Jun 03, 2015, 05:59 ET